Janssen has presented new data from across its oncology pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Talquetamab Talquetamab is an investigational GPRC5D-directed bispecific antibody currently in clinical development. Updated results from the Phase II MonumenTAL-1 study show that… Read More
The Janssen Pharmaceutical Companies of Johnson & Johnson have submitted a Type II variation application to the European Medicines Agency (EMA) seeking approval of Carvykti (ciltacabtagene autoleucel; cilta-cel) for relapsed and lenalidomide-refractory multiple myeloma. The application is supported by data from the Phase III CARTITUDE-4 study, which evaluated the safety… Read More
The European Commission (EC) has granted marketing authorisation for Akeega (niraparib and abiraterone acetate [AA]) for adults with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2 mutations (germline and/or somatic). The drug is given in the form of a dual action tablet (DAT), with prednisone or prednisolone, and is approved in… Read More
New data has revealed a long-term response in patients with advanced non-small cell lung cancer (NSCLC) taking Rybrevant (amivantamab). The CHRYSALIS study is evaluating amivantamab in patients with advanced non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease… Read More
Janssen has revealed updated results from the Phase III MAGNITUDE study, which show that a combination therapy including niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, slowed prostate cancer progression. The drug was investigated in combination with abiraterone acetate plus prednisone (AAP) in patients with metastatic castration-resistant prostate… Read More
An investigational HIV vaccine regimen was safe but did not provide protection against HIV, an independent data and safety monitoring board (DSMB) has determined. The regimen was tested among men who have sex with men (MSM) and transgender people. The HPX3002/HVTN 706, or ‘Mosaico’, Phase III clinical… Read More
Janssen has submitted a marketing authorisation application (MAA) seeking approval of talquetamab in Europe for the treatment of patients with relapsed or refractory multiple myeloma (RRMM). Talquetamab is an investigational, off-the-shelf, bispecific T-cell engager antibody targeting both GPRC5D, a novel drug target that is on some normal… Read More
Jannsen has revealed clinical trial results for its pipeline of products to treat multiple myeloma and leukaemia. The findings were presented at the American Society of Hematology (ASH) 2022 Annual Meeting taking place in New Orleans, US. Along with positive Phase… Read More
